US Pharma MarketingSuperluminal secures $60M for Phase 1 of genetic obesity drug
Superluminal Medicines raises $60M Series B for Phase 1 trials of MC4R obesity drug, backed by investors including Eli Lilly, RA Capital and Nvidia Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing:…
A Boston biotech following in the footsteps of Rhythm Pharmaceuticals and others in the MC4R obesity field has raised $60 million to test its approach in Phase 1.
Superluminal Medicines secured the Series B from ...
Source: Endpoints News